Cleveland Alzheimers Disease Research Center

克利夫兰阿尔茨海默病研究中心

基本信息

批准号：
10263707
负责人：
JAMES Bruce LEVERENZ
金额：
$ 309.02万
依托单位：
CLEVELAND CLINIC LERNER COM-CWRU
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10263707
关键词：
Address African American Aging Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Autopsy Behavioral Biological Markers Biology Brain Brain Diseases Cessation of life Clinic Clinical Clinical Research Cognitive Collaborations Collection Communities Consent Data Data Analyses Dementia Dementia with Lewy Bodies Development Diagnosis Disease Disease Progression Enrollment Ensure Evaluation Financial Support Fostering Foundations Freezing Funding Genetic Genetic Risk Goals Heterogeneity Human Image Impairment Individual Infrastructure Institutes Institution International Intervention Laboratory Finding Link Magnetic Resonance Imaging Medical center Memory Molecular Monitor Motor National Institute on Aging Ohio Participant Pathologic Pathology Persons Phenotype Physicians Population Research Research Design Research Personnel Resources Risk Risk Factors Scientist Speed Standardization Structure System Therapeutic Time Tissue Sample Tissues Training Translating Translational Research Translations Underrepresented Populations United States Department of Veterans Affairs United States National Institutes of Health Universities University Hospitals Veterans amyloid imaging base career career development cell repository cohort collaborative environment community center data management data repository design drug discovery education research ethnic minority population health disparity high risk imaging biomarker improved individualized medicine insight mild cognitive impairment neuroimaging neuropathology next generation novel therapeutics outreach participant retention patient engagement precision medicine programs protective factors racial minority recruit social stigma statistics success targeted biomarker therapeutic target tool

项目摘要

PROJECT SUMMARY The Cleveland Alzheimer's Disease Research Center (CADRC) is a collaborative effort of physicians and investigators from Case Western Reserve University (CWRU), Cleveland Clinic Foundation (CCF), MetroHealth System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center (LSCVAMC), to foster excellence in research and facilitate discovery as an established National Institute on Aging (NIA) funded Alzheimer's Disease Research Center. The CADRC represents a rich clinical and research community and an estimated 220,000 Ohioans who suffer from Alzheimer's disease (AD) or AD-related dementias (ADRD). The CADRC has 8 Cores and a Research Education Component designed to create the foundation that will enhance the research efforts of the Northeast Ohio AD/ADRD research community, as well as add unique value to the national Alzheimer's Disease Research Centers (ADRC) program and other national and international research programs. The CADRC is focused on participants that will help us understand the pathobiology of clinical and pathological heterogeneity observed in dementia including atypical and amnestic AD, dementia with Lewy bodies, cognitively normal individuals with different levels of genetic risk for AD, and diversity of participant populations (Clinical and Outreach, Recruitment, and Engagement Cores). To support the CADRC goals, the focus will be on deep phenotyping of participants with longitudinal and systematic cognitive, behavioral and motor characterization (Clinical Core), genetic and biofluid biomarker collection and analysis (Biomarker Core), imaging (Neuroimaging Core), and autopsy after death (Neuropathology Core). Results will be shared with the research community in a timely and regular manner to allow other investigators to benefit from the CADRC efforts (Data Management and Statistics Core). In addition, the CADRC will train the next generation of investigators utilizing a rigorous and well-designed Research Education Component, support translation of new laboratory findings through the Translational Therapeutics Core, and support high risk/high gain projects through the developmental program as a part of the Administrative Core. The ultimate goals are to advance the precision medicine approach to dementia diagnosis and treatment, support the development of early stage investigators, assist all stages of investigators with tools for performing human-based research, and better engage underrepresented populations in AD/ADRD research.

项目摘要克利夫兰阿尔茨海默氏病研究中心（CADRC）是医生的合作努力克利夫兰诊所基金会（CCF）的Case Western Reserve University（CWRU）的研究人员， Metrohealth系统（MHS），大学医院（UH）和Louis Stokes Cleveland VA医疗中心（LSCVAMC），以促进研究并促进作为既定国家研究所的发现老化（NIA）资助的阿尔茨海默氏病研究中心。 CADRC代表了丰富的临床和研究社区和估计有220,000名俄亥俄州的俄亥俄州人（AD）或与广告有关痴呆症（ADRD）。 CADRC有8个核心和一个研究教育部分，旨在创建基金会将加强东北俄亥俄州广告/ADRD研究社区的研究工作随着为国家阿尔茨海默氏病研究中心（ADRC）计划和其他国家和国际研究计划。 CADRC专注于将帮助我们的参与者了解在痴呆症中观察到的临床和病理异质性的病理生物学和敏感的AD，痴呆症有Lewy身体，具有不同遗传风险水平的认知正常人对于AD以及参与者人群的多样性（临床和外展，招聘和参与核心）。为了支持CADRC目标，重点将放在纵向和系统的认知，行为和运动表征（临床核心），遗传和生物流体生物标志物收集和分析（生物标志物核心），成像（神经成像核心）和死亡后的尸检（神经病理学核心）。结果将及时，定期与研究社区共享允许其他研究人员从CADRC工作（数据管理和统计核心）中受益。在此外，CADRC将利用严格且精心设计的下一代调查人员培训研究教育部分，通过翻译支持新实验室发现的翻译治疗核心，并通过发展计划来支持高风险/高收益项目行政核心。最终目标是推进精确的医学方法诊断和治疗，支持早期研究人员的发展，协助研究人员的所有阶段借助进行基于人类的研究的工具，并更好地参与代表性不足的人群广告/ADRD研究。